Compare NCLH & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCLH | GKOS |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4B | 8.7B |
| IPO Year | 2011 | 2015 |
| Metric | NCLH | GKOS |
|---|---|---|
| Price | $19.78 | $156.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | $24.76 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 15.8M | 768.7K |
| Earning Date | 05-04-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $5,396,175,000.00 | $507,442,000.00 |
| Revenue This Year | $9.96 | $23.32 |
| Revenue Next Year | $6.60 | $27.43 |
| P/E Ratio | $84.63 | ★ N/A |
| Revenue Growth | 10.71 | ★ 32.33 |
| 52 Week Low | $14.53 | $73.16 |
| 52 Week High | $27.18 | $156.60 |
| Indicator | NCLH | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 70.99 |
| Support Level | $17.73 | $96.44 |
| Resistance Level | $20.82 | N/A |
| Average True Range (ATR) | 0.83 | 6.26 |
| MACD | -0.17 | 0.87 |
| Stochastic Oscillator | 44.94 | 98.90 |
Norwegian Cruise Line is the world's third-largest publicly traded cruise company by berths (around 71,000). It operates 34 ships across three brands—Norwegian, Oceania, and Regent Seven Seas—offering both freestyle and luxury cruising. The company redeployed its entire fleet as of May 2022. With 17 passenger vessels on order among its brands through 2037, representing 46,000 incremental berths, Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sails to around 700 global destinations.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.